BST Special Trade Update: December 30, 2013
December 30, 2013
With 2013 quickly drawing to a close, I’d like to take a few minutes to share my thoughts about a biotech stock that I’m particularly excited about for 2014. You see, if all goes as planned with a certain company’s leading drug candidate, its stock price could skyrocket next year.
The company I’m referring to is none other than Cyclacel Pharmaceuticals(NASDAQ: CYCC).
Many of you probably recall that we just recommended CYCC this past September. But if you missed the trade or just need to refresh your memory, you can read the Trade Alert in its entirety by clicking here.
Now, since our recommendation was released, CYCC has moved higher in a hurry. The stock’s up more than 25% as I write. And at one point, we had a whopping 79% gain on the position.
That’s stellar performance in just three months time!
With that said, we think this is just the beginning of much bigger upward move for CYCC. Here’s why…
First off, the company’s leading drug candidate – sapacitabine – has demonstrated in phase 2 testing that it is both safer and more effective than existing treatments for two kinds of cancer… Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).
Another reason we’re excited about CYCC is that it also has potential to treat much larger patient populations suffering from ovarian, breast, and pancreatic cancers. Recent trial results show that a combination of sapacitabine and the company’s other major drug candidate, seliciclib, demonstrated activity against solid tumors caused by these cancers.
And last but not least, Cyclacel has important catalysts happening in 2014.
The company plans on providing an update about its pivotal development strategy for sapacitabine as a treatment for MDS around mid-year. Plus, the final results from the phase 3 trial of sapacitabine in AML are expected in the fourth quarter of 2014.
There you have it…
CYCC has a revolutionary anti-cancer drug in late-stage clinical testing with potential to address multi-billion dollar markets. And the company will provide key information next year that will give insight about the drug’s potential for success.
Like I said… we’re really excited about CYCC for 2014.
In fact, we’re so pumped up that we’ve put together a special report all about CYCC.
The title of this one-of-a-kind report is… “The End of Cancer Worries Forever”. And as a subscriber, you can download it free of charge from the Members Only Special Reports page of our website. Take a few minutes to check it out.
One last note before I wrap this up…
In light of our bullish outlook for CYCC, we’re going to move the stock from Hold to Buy. And we’re raising our maximum buy price up to $5.00 per share.
So, if you missed out on CYCC the first time around, you now have a second chance to get in on the action. Don’t let this opportunity pass you by. There’s no telling just how long this amazing biotech will stay in our buy range.
Happy Holidays and Happy New Year from all of us here at Biotech Supertrader! We can’t wait to bring you many more exciting and profitable trades in the biotech space in 2014!
Action To Take
- Move Cyclacel Pharmaceuticals (NASDAQ: CYCC) from Hold to Buy and adjust maximum buy price to $5.00.
Category: BST Trade Alert
